Neurological Involvement in Tetrahydrobiopterin Deficiency

Abstract

Tetrahydrobiopterin (BH4) is a natural and essential cofactor for the enzymatic hydroxylation of phenylalanine (Phe) and tyrosine (Tyr), and for two tryptophan hydroxylases, three nitric oxide synthases, and glyceryl-ether monooxygenase. Five separate genetic conditions affecting BH4 synthesis or recycling have been identified so far, including deficiency in (1) 6-pyruvoyltetrahydropterin synthase; (2) dihydropteridine reductase; (3) GTP cyclohydrolase I; (4) sepiapterin reductase; and (5) pterin-4α-carbinolamine dehydratase. These disorders cause hyperphenylalaninemia and impaired synthesis of serotonin and dopamine since tyrosine hydroxylase and neuronal tryptophan hydroxylase require BH4 and serotonin/dopamine products (5-hydroxytryptophan and L-dopa). All these five genetic conditions can be identified by newborn screening procedures due to elevated blood levels of Phe (with the sole exception of sepiapterin reductase deficiency). BH4 loading tests and measurement of neurotransmitter metabolites, pterins, and folates in cerebrospinal fluid can add further important information on disease severity. Untreated patients develop a complex neurological phenotype, which includes Parkinson-like features, brain degeneration, and early death. The gold standard treatment of severe disorders of BH4 metabolism is based on replacement therapy with BH4, 5-hydroxytryptophan, L-dopa, and carbidopa, with the addition, in certain cases, of folinic acid supplements and pramipexole. Dopamine agonists can improve L-dopa therapy, making treatment easier, relieving symptoms, stabilizing clinical course, and possibly ameliorating long-term outcomes. The outcome of patients with disorders of biopterin synthesis can be favorable, with either normal or near-normal cognition, and with some residual neurological symptoms usually manifesting diurnal variation, that is, worst when patients become tired or when the dosage or interval for medications is inadequate.

Keywords

tetrahydrobiopterin - hyperphenylalaninemia - dihydropteridine reductase - GTP cyclohydrolase I - homovanillic acid - pterin-4′-carbinolamine dehydratase - phenylalanine - 6-pyruvoyltetrahydropterin synthase - sepiapterin reductase

• References

• 1 Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet 2010; 376 (9750) 1417-1427
• 2 Blau N, Hennermann JB, Langenbeck U, Lichter-Konecki U. Diagnosis, classification, and genetics of phenylketonuria and tetrahydrobiopterin (BH4) deficiencies. Mol Genet Metab 2011; 104 (Suppl): S2-S9
• 3 Longo N. Disorders of biopterin metabolism. J Inherit Metab Dis 2009; 32 (3) 333-342
• 4 Blau B, Thöny R, Cotton GH, Hyland K. Disorders of tetrahydrobiopterin and related biogenic amines. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Vogelstein B, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2001: 1725-1776
• 5 Dhondt JL. Laboratory diagnosis of phenylketonuria. In: Blau N, ed. PKU and BH4: Advances in Phenylketonuria and Tetrahydrobiopterin. Heilbronn: SPS Verlagsgesellschaft; 2006: 161-179
• 6 Porta F, Ponzone A, Spada M. Short prolactin profile for monitoring treatment in BH4 deficiency. Eur J Paediatr Neurol 2015; 19 (3) 360-363
• 7 Niederwieser A, Blau N, Wang M, Joller P, Atarés M, Cardesa-Garcia J. GTP cyclohydrolase I deficiency, a new enzyme defect causing hyperphenylalaninemia with neopterin, biopterin, dopamine, and serotonin deficiencies and muscular hypotonia. Eur J Pediatr 1984; 141 (4) 208-214
• 8 Maita N, Okada K, Hatakeyama K, Hakoshima T. Crystal structure of the stimulatory complex of GTP cyclohydrolase I and its feedback regulatory protein GFRP. Proc Natl Acad Sci U S A 2002; 99 (3) 1212-1217
• 9 Ponzone A, Spada M, Ferraris S, Dianzani I, de Sanctis L. Dihydropteridine reductase deficiency in man: from biology to treatment. Med Res Rev 2004; 24 (2) 127-150
• 10 Jäggi L, Zurflüh MR, Schuler A , et al. Outcome and long-term follow-up of 36 patients with tetrahydrobiopterin deficiency. Mol Genet Metab 2008; 93 (3) 295-305
• 11 Leuzzi V, Carducci CA, Carducci CL , et al. Phenotypic variability, neurological outcome and genetics background of 6-pyruvoyl-tetrahydropterin synthase deficiency. Clin Genet 2010; 77 (3) 249-257
• 12 Pavone P, Spalice A, Polizzi A, Parisi P, Ruggieri M. Ohtahara syndrome with emphasis on recent genetic discovery. Brain Dev 2012; 34 (6) 459-468
• 13 Pavone P, Striano P, Falsaperla R, Pavone L, Ruggieri M. Infantile spasms syndrome, West syndrome and related phenotypes: what we know in 2013. Brain Dev 2014; 36 (9) 739-751
• 14 Van der Knaap M, Valk J. Magnetic Resonance of Myelination and Myelin Disorders. 3rd ed. Berlin: Springer-Verlag; 2005
• 15 Patay Z. Metabolic disorders. In: Tortori-Donati P, ed. Pediatric Neuroradiology. Brain. . Berlin: Springer-Verlag; 2005: 543-722
• 16 Barkovich AJ. Pediatric Neuroradiology. 5th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2012
• 17 Porta F, Mussa A, Concolino D, Spada M, Ponzone A. Dopamine agonists in dihydropteridine reductase deficiency. Mol Genet Metab 2012; 105 (4) 582-584
• 18 Neville BG, Parascandalo R, Farrugia R, Felice A. Sepiapterin reductase deficiency: a congenital dopa-responsive motor and cognitive disorder. Brain 2005; 128 (Pt 10) 2291-2296
• 19 Abeling NG, Duran M, Bakker HD , et al. Sepiapterin reductase deficiency an autosomal recessive DOPA-responsive dystonia. Mol Genet Metab 2006; 89 (1–2) 116-120
• 20 Opladen T, Abu Seda B, Rassi A, Thöny B, Hoffmann GF, Blau N. Diagnosis of tetrahydrobiopterin deficiency using filter paper blood spots: further development of the method and 5 years experience. J Inherit Metab Dis 2011; 34 (3) 819-826
• 21 Hyland K, Surtees RA, Heales SJ, Bowron A, Howells DW, Smith I. Cerebrospinal fluid concentrations of pterins and metabolites of serotonin and dopamine in a pediatric reference population. Pediatr Res 1993; 34 (1) 10-14
• 22 Zorzi G, Thöny B, Blau N. Reduced nitric oxide metabolites in CSF of patients with tetrahydrobiopterin deficiency. J Neurochem 2002; 80 (2) 362-364
• 23 Hyland K. Inherited disorders affecting dopamine and serotonin: critical neurotransmitters derived from aromatic amino acids. J Nutr 2007; 137 (6) (Suppl. 01) 1568S-1572S , discussion 1573S–1575S
• 24 Hyland K. Clinical utility of monoamine neurotransmitter metabolite analysis in cerebrospinal fluid. Clin Chem 2008; 54 (4) 633-641
• 25 Curtius HC, Niederwieser A, Viscontini M , et al. Atypical phenylketonuria due to tetrahydrobiopterin deficiency. Diagnosis and treatment with tetrahydrobiopterin, dihydrobiopterin and sepiapterin. Clin Chim Acta 1979; 93 (2) 251-262
• 26 Ponzone A, Guardamagna O, Dianzani I , et al. Catalytic activity of tetrahydrobiopterin in dihydropteridine reductase deficiency and indications for treatment. Pediatr Res 1993; 33 (2) 125-128
• 27 Bonafé L, Thöny B, Penzien JM, Czarnecki B, Blau N. Mutations in the sepiapterin reductase gene cause a novel tetrahydrobiopterin-dependent monoamine-neurotransmitter deficiency without hyperphenylalaninemia. Am J Hum Genet 2001; 69 (2) 269-277
• 28 Bartholomé K, Byrd DJ. Letter: L-dopa and 5-hydroxytryptophan therapy in phenylketonuria with normal phenylalanine-hydroxylase activity. Lancet 1975; 2 (7943) 1042-1043
• 29 Schuler A, Blau N, Ponzone A. Monoamine oxidase inhibitors in tetrahydrobiopterin deficiency. Eur J Pediatr 1995; 154 (12) 997
• 30 Ponzone A, Baglieri S, Battistoni G, Martini A, Spada M. COMT inhibitors in the treatment of tetrahydrobiopterin deficiency. Pteridines 2001; 12: 70
• 31 Tanaka Y, Matsuo N, Tsuzaki S, Araki K, Tsuchiya Y, Niederwieser A. On-off phenomenon in a child with tetrahydrobiopterin deficiency due to 6-pyruvoyl tetrahydropterin synthase deficiency (BH4 deficiency). Eur J Pediatr 1989; 148 (5) 450-452
• 32 Porta F, Mussa A, Concolino D, Spada M, Ponzone A. Dopamine agonists in 6-pyruvoyl tetrahydropterin synthase deficiency. Neurology 2009; 73 (8) 633-637
• 33 Liu KM, Liu TT, Lee NC, Cheng LY, Hsiao KJ, Niu DM. Long-term follow-up of Taiwanese Chinese patients treated early for 6-pyruvoyl-tetrahydropterin synthase deficiency. Arch Neurol 2008; 65 (3) 387-392
• 34 Dudesek A, Röschinger W, Muntau AC , et al. Molecular analysis and long-term follow-up of patients with different forms of 6-pyruvoyl-tetrahydropterin synthase deficiency. Eur J Pediatr 2001; 160 (5) 267-276
• 35 Echenne B, Roubertie A, Assmann B , et al. Sepiapterin reductase deficiency: clinical presentation and evaluation of long-term therapy. Pediatr Neurol 2006; 35 (5) 308-313